Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Open-Label Cross-Over Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Patients With HER2-Positive Early Breast Cancer
Conditions
Interventions
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Pertuzumab IV
+1 more
Locations
40
United States
Rocky Mountain Cancer Center - Lakewood (West)
Lakewood, Colorado, United States
Illinois Cancer Care
Peoria, Illinois, United States
Cancer Center of Kansas
Wichita, Kansas, United States
Maryland Oncology Hematology
Rockville, Maryland, United States
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Start Date
December 19, 2018
Primary Completion Date
February 24, 2020
Completion Date
October 12, 2022
Last Updated
January 2, 2024
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions